Answers are grounded in this paper and cite their sources.
Background: Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs), has substantially changed the treatment of advanced malignancies. By blocking inhibitory immune pathways such as programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), these agents enhance antitumour immune activity. However, the same immune activation can produce inflammatory toxicities known as immune-related adverse events (irAEs), which may involve almost any organ system. Objective: To review the mechanisms, clinical spectrum, risk factors, diagnosis, management, and long-term considerations associated with adverse drug reactions caused by cancer immunotherapy, with emphasis on evidence from original clinical, observational, translational, and pharmacovigilance studies. Methods: A narrative literature review incorporating elements of systematic search methodology was conducted. PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar were searched for original research articles published between January 2010 and August 2026. Results: Clinical studies demonstrate that irAEs can affect the skin, gastrointestinal tract, liver, endocrine organs, lungs, kidneys, cardiovascular system, nervous system, and musculoskeletal system. Toxicity varies according to the checkpoint pathway targeted, treatment regimen, cancer type, and patient characteristics. Combination CTLA-4/PD-1 blockade is generally associated with a broader and more frequent toxicity profile than monotherapy. Gastrointestinal toxicity, endocrinopathies, pneumonitis, myocarditis, nephrotoxicity, and neurological toxicity may require treatment interruption or immunosuppressive therapy. Emerging research indicates that T-cell phenotypes and gut microbiome composition may contribute to susceptibility to irAEs. Management generally involves early recognition, exclusion of alternative causes, interruption of immunotherapy according to severity, corticosteroid therapy for clinically significant inflammatory toxicity, and organ-specific immunomodulation for steroid-refractory disease. Conclusion: Adverse drug reactions associated with cancer immunotherapy represent a clinically heterogeneous group of toxicities requiring multidisciplinary recognition and management. Increasing evidence from prospective cohorts, real-world studies, and biomarker investigations is improving understanding of their mechanisms and risk factors. Continued research is required to identify reliable predictive biomarkers, optimize immunosuppression, and establish safer strategies for immunotherapy rechallenge.
No takes yet. Share an insight, caveat, or question.
Venkatesh et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: